An update on irritable bowel syndrome: From diagnosis to emerging therapies

Current Opinion in Gastroenterology

Volumn 27, Issue 1, 2011, Pages 72-78

  Changa, Joseph Y ^a,b   Talley, Nicholas J ^b  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

Bacterial overgrowth; Constipation; Diarrhea; Irritable bowel syndrome; Mast cells; Therapy; Treatment

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; ASIMADOLINE; GROWTH HORMONE SECRETAGOGUE; GUANINE NUCLEOTIDE BINDING PROTEIN; HISTAMINE; KETOTIFEN; LINACLOTIDE; LOPERAMIDE; MESALAZINE; PEPPERMINT OIL; POLYCARBOPHIL CALCIUM; RIFAXIMIN; SCOPOLAMINE; SEROTONIN; SEROTONIN TRANSPORTER; TOFISOPAM; TRYPTASE;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ARTICLE; BACTERIAL OVERGROWTH; BLOATING; CONSTIPATION; DIARRHEA; DISEASE MARKER; GASTROINTESTINAL MOTILITY; GENETIC ASSOCIATION; HUMAN; HYPERSENSITIVITY; IMMUNE FUNCTION TEST; IRRITABLE COLON; MAST CELL; SEROTONINERGIC SYSTEM;

HUMANS; IRRITABLE BOWEL SYNDROME;

EID: 79951679052     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOG.0b013e3283414065     Document Type: Article

References (75)

1. Drossman DA, Camilleri M, Mayer EA, et al. AGA technical review on irritable bowel syndrome. Gastroenterology 2002; 123:2108-2131. (Pubitemid 35408332)
2. Saito YA, Schoenfeld P, Locke GR III. The epidemiology of irritable bowel syndrome in North America: A systematic review. Am J Gastroenterol 2002; 97:1910-1915.
3. Chang JY, Locke GR III, McNally MA, et al. Impact of functional gastrointestinal disorders on survival in the community. Am J Gastroenterol 2010; 105:822-832. Reassuring findings from a large population-based study that demonstrated that IBS did not impact survival.
4. Sandler RS, Everhart JE, Donowitz M, et al. The burden of selected digestive diseases in the United States. Gastroenterology 2002; 122:1500-1511. (Pubitemid 34465190)
5. Spiegel BM. The burden of IBS: Looking at metrics. Curr Gastroenterol Rep 2009; 11:265-269.
6. Talley NJ, Boyce PM, Jones M. Predictors of health care seeking for irritable bowel syndrome: A population-based study. Gut 1997; 41:394-398. (Pubitemid 27428202)
7. Halpert A, Drossman D. Biopsychosocial issues in irritable bowel syndrome. J Clin Gastroenterol 2005; 39:665-669. (Pubitemid 41177083)
8. Camilleri M. Serotonin in the gastrointestinal tract. Curr Opin Endocrinol Diabetes Obes 2009; 16:53-59.
9. Khan WI, Ghia JE. Gut hormones: Emerging role in immune activation and inflammation. Clin Exp Immunol 2010; 161:19-27.
10. Atkinson W, Lockhart S, Whorwell PJ, et al. Altered 5-hydroxytryptamine signaling in patients with constipation- and diarrhea-predominant irritable bowel syndrome. Gastroenterology 2006; 130:34-43. (Pubitemid 43049833)
11. Dunlop SP, Coleman NS, Blackshaw E, et al. Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel syndrome. Clin Gastroenterol Hepatol 2005; 3:349-357. (Pubitemid 40488343)
12. Houghton LA, Atkinson W, Whitaker RP, et al. Increased platelet depleted plasma 5-hydroxytryptamine concentration following meal ingestion in symptomatic female subjects with diarrhoea predominant irritable bowel syndrome. Gut 2003; 52:663-670. (Pubitemid 36528867)
13. Coates MD, Mahoney CR, Linden DR, et al. Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome. Gastroenterology 2004; 126:1657-1664. (Pubitemid 38736329)
14. Camilleri M, Andrews CN, Bharucha AE, et al. Alterations in expression of p11 and SERT in mucosal biopsy specimens of patients with irritable bowel syndrome. Gastroenterology 2007; 132:17-25. (Pubitemid 46108754)
15. Andresen V, Montori VM, Keller J, et al. Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: A systematic review and meta-analysis of randomized controlled trials. Clin Gastroenterol Hepatol 2008; 6:545-555.
16. Brandt LJ, Chey WD, Foxx-Orenstein AE, et al. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol 2009; 104 (Suppl 1):S1-S35.
17. Cremonini F, Delgado-Aros S, Camilleri M. Efficacy of alosetron in irritable bowel syndrome: A meta-analysis of randomized controlled trials. Neurogastroenterol Motil 2003; 15:79-86. (Pubitemid 36313138)
18. Ford AC, Brandt LJ, Young C, et al. Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: Systematic review and meta-analysis. Am J Gastroenterol 2009; 104:1831-1843; quiz 1844.
19. Lesbros-Pantoflickova D, Michetti P, Fried M, et al. Meta-analysis: The treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2004; 20:1253-1269. (Pubitemid 40040072)
20. Mayer EA, Berman S, Derbyshire SW, et al. The effect of the 5-HT3 receptor antagonist, alosetron, on brain responses to visceral stimulation in irritable bowel syndrome patients. Aliment Pharmacol Ther 2002; 16:1357-1366.
21. Evans BW, Clark WK, Moore DJ, et al. Tegaserod for the treatment of irritable bowel syndrome and chronic constipation. Cochrane Database Syst Rev 2007:CD003960.
22. Jones BW, Moore DJ, Robinson SM, et al. A systematic review of tegaserod for the treatment of irritable bowel syndrome. J Clin Pharm Ther 2002; 27:343-352. (Pubitemid 35286232)
23. Kanazawa M, Endo Y, Whitehead WE, et al. Patients and nonconsulters with irritable bowel syndrome reporting a parental history of bowel problems have more impaired psychological distress. Dig Dis Sci 2004; 49:1046-1053. (Pubitemid 39012293)
24. Levy RL, WhiteheadWE, Von Korff MR, et al. Intergenerational transmission of gastrointestinal illness behavior. Am J Gastroenterol 2000; 95:451-456. (Pubitemid 30106175)
25. Locke GR III, Zinsmeister AR, Talley NJ, et al. Familial association in adults with functional gastrointestinal disorders. Mayo Clin Proc 2000; 75:907-912.
26. Saito YA, Petersen GM, Larson JJ, et al. Familial aggregation of irritable bowel syndrome: A family case-control study. Am J Gastroenterol 2010; 105:833-841. Family case-control study that directly surveyed symptoms from family members and demonstrated that IBS aggregates strongly in families.
27. Saito YA, Mitra N, Mayer EA. Genetic approaches to functional gastrointestinal disorders. Gastroenterology 2010; 138:1276-1285. Discussion on the genetic approach to IBS, current evidence for a genetic component to IBS, as well as future direction.
28. Andresen V, Camilleri M, Kim HJ, et al. Is there an association between GNbeta3-C825T genotype and lower functional gastrointestinal disorders? Gastroenterology 2006; 130:1985-1994. (Pubitemid 43816949)
29. Kim HJ, Camilleri M, Carlson PJ, et al. Association of distinct alpha(2) adrenoceptor and serotonin transporter polymorphisms with constipation and somatic symptoms in functional gastrointestinal disorders. Gut 2004; 53:829-837. (Pubitemid 38662132)
30. Saito YA, Locke III GR , Zimmerman JM, et al. A genetic association study of 5-HTT LPR and GNbeta3 C825T polymorphisms with irritable bowel syndrome. Neurogastroenterol Motil 2007; 19:465-470. (Pubitemid 46905394)
31. Ohman L, Simren M. Pathogenesis of IBS: Role of inflammation, immunity and neuroimmune interactions. Nat Rev Gastroenterol Hepatol 2010; 7:163-173.
32. Guilarte M, Santos J, de Torres I, et al. Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum. Gut 2007; 56:203-209.
33. Piche T, Saint-Paul MC, Dainese R, et al. Mast cells and cellularity of the colonic mucosa correlated with fatigue and depression in irritable bowel syndrome. Gut 2008; 57:468-473. (Pubitemid 351442529)
34. Barbara G, Stanghellini V, De Giorgio R, et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 2004; 126:693-702. (Pubitemid 38298317)
35. Walker MM, Talley NJ, Prabhakar M, et al. Duodenal mastocytosis, eosinophilia and intraepithelial lymphocytosis as possible disease markers in the irritable bowel syndrome and functional dyspepsia. Aliment Pharmacol Ther 2009; 29:765-773.
36. Muller-Lissner S, Kamm MA, Musoglu A, et al. Safety, tolerability, and efficacy of tegaserod over 13 months in patients with chronic constipation. Am J Gastroenterol 2006; 101:2558-2569; quiz 2671. (Pubitemid 44665253)
37. Parkes GC, Brostoff J, Whelan K, et al. Gastrointestinal microbiota in irritable bowel syndrome: Their role in its pathogenesis and treatment. Am J Gastroenterol 2008; 103:1557-1567. (Pubitemid 351813918)
38. Pimentel M, Chow EJ, Lin HC. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol 2000; 95:3503-3506.
39. PimentelM, Park S, Mirocha J, et al. The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: A randomized trial. Ann Intern Med 2006; 145:557-563. (Pubitemid 46780934)
40. Bratten JR, Spanier J, Jones MP. Lactulose breath testing does not discriminate patients with irritable bowel syndrome from healthy controls. Am J Gastroenterol 2008; 103:958-963. (Pubitemid 351501116)
41. Pimentel M. Evaluating a bacterial hypothesis in IBS using a modification of Koch's postulates. Part 1. Am J Gastroenterol 2010; 105:718-721.
42. Ford AC, Spiegel BM, Talley NJ, et al. Small intestinal bacterial overgrowth in irritable bowel syndrome: Systematic review and meta-analysis. Clin Gastroenterol Hepatol 2009; 7:1279-1286.
43. Lembo AJ, Zakko SF, Ferreira NL, et al. Rifaximin for the treatment of diarrheaassociated irritable bowel syndrome: Short term treatment leading to long term sustained response. Gastroenterology 2008; 134:A-545.
44. Pimentel M. An evidence-based treatment algorithm for IBS based on a bacterial/SIBO hypothesis: Part 2. Am J Gastroenterol 2010; 105:1227-1230.
45. Tana C, Umesaki Y, Imaoka A, et al. Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome. Neurogastroenterol Motil 2010; 22:512-519; e114-e115. Results support that fecal microbiota as well as organic acids are altered in IBS patients, and higher organic acid levels may impact abdominal symptoms and quality of life.
46. Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology 2006; 130:1480-1491.
47. Thompson WGCF, Drossman DA, et al. Functional bowel disease and functional abdominal pain. Gastroenterol Int 1992; 5:75-91.
48. Thompson WGLG, Drossman DA, et al. Functional bowel disease and functional abdominal pain. Gut 1999; 45 (Suppl 2):II43-II47. (Pubitemid 29434812)
49. Ford AC, Talley NJ, Veldhuyzen van Zanten SJ, et al. Will the history and physical examination help establish that irritable bowel syndrome is causing this patient's lower gastrointestinal tract symptoms? JAMA 2008; 300:1793-1805.
50. Jellema P, van der Windt DA, Schellevis FG, et al. Systematic review: Accuracy of symptom-based criteria for diagnosis of irritable bowel syndrome in primary care. Aliment Pharmacol Ther 2009; 30:695-706.
51. Whitehead WE, Drossman DA. Validation of symptom-based diagnostic criteria for irritable bowel syndrome: A critical review. Am J Gastroenterol 2010; 105:814-820; quiz 813, 821.
52. Spiller RC, Thompson WG. Bowel disorders. Am J Gastroenterol 2010; 105:775-785.
53. Camilleri M, Andresen V. Current and novel therapeutic options for irritable bowel syndrome management. Dig Liver Dis 2009; 41:854-862.
54. Quartero AO, Meineche-Schmidt V, Muris J, et al. Bulking agents, antispasmodic and antidepressant medication for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2005:CD003460.
55. Bijkerk CJ, Muris JW, Knottnerus JA, et al. Systematic review: The role of different types of fibre in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2004; 19:245-251. (Pubitemid 38253498)
56. Ford AC, Talley NJ, Spiegel BM, et al. Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: Systematic review and meta-analysis. BMJ 2008; 337:2313; doi: 10.1136/bmj.a2313.
57. Jailwala J, Imperiale TF, Kroenke K. Pharmacologic treatment of the irritable bowel syndrome: A systematic review of randomized, controlled trials. Ann Intern Med 2000; 133:136-147. (Pubitemid 30490414)
58. Bouras EP, Camilleri M, Burton DD, et al. Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder. Gastroenterology 2001; 120:354-360. (Pubitemid 32147632)
59. Camilleri M, Kerstens R, Rykx A, et al. A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med 2008; 358:2344-2354. (Pubitemid 351749158)
60. Quigley EM, Vandeplassche L, Kerstens R, et al. Clinical trial: The efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation - a 12-week, randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther 2009; 29:315-328.
61. Tack J, van Outryve M, BeyensG, et al. Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives. Gut 2009; 58:357-365.
62. Camilleri M, Bharucha AE, Ueno R, et al. Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers. Am J Physiol Gastrointest Liver Physiol 2006; 290:G942-G947.
63. Ginzburg R, Ambizas EM. Clinical pharmacology of lubiprostone, a chloride channel activator in defecation disorders. Expert Opin Drug Metab Toxicol 2008; 4:1091-1097.
64. Lacy BE, Chey WD. Lubiprostone: Chronic constipation and irritable bowel syndrome with constipation. Expert Opin Pharmacother 2009; 10:143-152.
65. Andresen V, Camilleri M, Busciglio IA, et al. Effect of 5 days linaclotide on transit and bowel function in females with constipation- predominant irritable bowel syndrome. Gastroenterology 2007; 133:761-768. (Pubitemid 47374145)
66. Johnston JM, Kurtz CB, Drossman DA, et al. Pilot study on the effect of linaclotide in patients with chronic constipation. Am J Gastroenterol 2009; 104:125-132.
67. Lembo AJ, Kurtz CB, MacDougall JE, et al. Efficacy of linaclotide for patients with chronic constipation. Gastroenterology 2010; 138:886-895. Results from a multicenter, placebo-controlled, parallel-group study of patients with chronic constipation that demonstrated sustained improvements of bowel habits, symptoms, and quality of life. May hold promise in C-IBS given these results.
68. Klooker TK, Braak B, Koopman KE, et al. The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome. Gut 2010; 59:1213-1221. This study demonstrated the role of mast cell stabilization in IBS with ketotifen shown to increase the threshold for discomfort in patients with IBS with visceral hypersensitivity, reduce IBS symptoms, and improve health-related quality of life.
69. Dunlop SP, Jenkins D, Neal KR, et al. Randomized, double-blind, placebocontrolled trial of prednisolone in postinfectious irritable bowel syndrome. Aliment Pharmacol Ther 2003; 18:77-84. (Pubitemid 36897983)
70. Corinaldesi R, Stanghellini V, Cremon C, et al. Effect of mesalazine on mucosal immune biomarkers in irritable bowel syndrome: A randomized controlled proofof- concept study. Aliment Pharmacol Ther 2009; 30:245-252. Mesalazine demonstrated to reduce mast cell infiltration in 20 IBS patients with improvements in general well being.
71. Jiang ZD, DuPont HL. Rifaximin: In vitro and in vivo antibacterial activity - a review. Chemotherapy 2005; 51 (Suppl 1):67-72. (Pubitemid 40663191)
72. Camilleri M. Novel pharmacology: Asimadoline, a kappa-opioid agonist, and visceral sensation. Neurogastroenterol Motil 2008; 20:971-979.
73. Mangel AW, Bornstein JD, Hamm LR, et al. Clinical trial: Asimadoline in the treatment of patients with irritable bowel syndrome. Aliment Pharmacol Ther 2008; 28:239-249. (Pubitemid 351861967)
74. Szarka LA, Camilleri M, Burton D, et al. Efficacy of on-demand asimadoline, a peripheral kappa-opioid agonist, in females with irritable bowel syndrome. Clin Gastroenterol Hepatol 2007; 5:1268-1275. (Pubitemid 350019057)
75. Leventer SM, Raudibaugh K, Frissora CL, et al. Clinical trial: Dextofisopam in the treatment of patients with diarrhoea-predominant or alternating irritable bowel syndrome. Aliment Pharmacol Ther 2008; 27:197-206. (Pubitemid 350256611)